News

Mydayis is a once-daily treatment and prescription medicine, which includes three different types of drug-releasing beads to control ADHD in patients 13 years and older. Shire plans to

The companies plan to initiate a Phase 2 open-label, randomized, non-comparative study to evaluate the safety, tolerability and efficacy of eFFECTOR’s investigational small molecule MNK1/2 inhibitor, eFT508, in

The event organized to mark the collaboration and the granting of the loan occurs today at the EIB Headquarters in Luxembourg, in presence of Mr. Ambroise Fayolle, EIB

Under the deal, Pamplona will purchase all of the outstanding shares of Parexel for $88.10 per share in cash, representing a 27.9% premium to its closing stock price

The action was taken by the biotechnology company after consultation with the Independent Data Monitoring Committee (IDMC) and a review of the unblinded data of the trial dubbed

In newborns, GBS manifests as sepsis, pneumonia, and meningitis, with potentially fatal outcomes for some, and long-lasting neurological damage in 46 to 50 percent of those infected. “Because

Dementia with Lewy bodies is the second-leading form of progressive dementia and affects over 1 million people in the United States. Currently, there are no approved therapies for

The approval has been granted for Rixathon to be used in all indications of the reference medicine, MabThera. Novartis has received approval for Rixathon to treat non-Hodgkin's lymphoma

The FDA has also approved the PFS trade name of Symjepi. Symjepi provides two single dose syringes of epinephrine (adrenaline), which is considered the drug of choice for